The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of myopia in children. Considered a common ...

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with ...

SRINAGAR: In a major breakthrough, the doctors at GMC Rajouri have administered atropine to treat 11 patients who fell ill from a mysterious illness in Badhal village of J&K’s Rajouri.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

For permission requests, please contact NEJM Reprints at [email protected] Select the format you want to export the citation of this publication.

Treated with atropine, the patients showed unexpected recovery, and doctors are awaiting details on the toxin to ensure long-term protection. No new cases emerged in the past four days.